journal article·2024-11Open access

LncRNA FAISL Inhibits Calpain 2‐Mediated Proteolysis of FAK to Promote Progression and Metastasis of Triple Negative Breast Cancer

Yunmei Zhang, Shiyu Wei, Zhengjie Chen, Rui Xu, Shu‐Rong Li, Lili You, Ruiyue Wu, Yin Zhang, Jian‐You Liao, Xiaoding Xu, Erwei Song, Man‐Li Luo

Advanced Science· Volume 11· Issue 42

Abstract

Abstract Triple negative breast cancer (TNBC) is the most aggressive subtype in breast tumors. When re‐analyzing TCGA breast cancer dataset, we found cell adhesion molecules are highly enriched in differentially expressed genes in TNBC samples, among which Focal Adhesion Kinase (FAK) is most significantly associated with poor survival of TNBC patients. FAK is precisely modulated in the focal adhesion dynamics. To investigate whether lncRNAs regulate FAK signaling, we performed RNA immunoprecipitation sequencing and found FAISL (FAK Interacting and Stabilizing LncRNA) abundantly enriched in FAK‐interacting lncRNAs and frequently overexpressed in TCGA TNBC tissues. FAISL promotes TNBC cell adhesion, cytoskeleton spreading, proliferation, and anchor‐independent survival. FAISL doesn't affect FAK mRNA but positively regulates FAK protein level by blocking Calpain 2‐mediated proteolysis. FAISL interacts with the C‐terminus domain of FAK, whereby masks the binding site of Calpain 2 and prevents FAK cleavage. High level of FAISL correlates with FAK expression in tumor tissues and poor prognosis of TNBC patients. A siRNA delivery system targeting FAISL using reduction‐responsive nanoparticles effectively inhibits tumor growth and metastasis in TNBC mouse models. Together, these findings uncover a lncRNA‐mediated mechanism of regulating FAK proteolysis in the TNBC progression, and highlight the potential of targeting lncRNA FAISL for TNBC treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · RNA and protein synthesis mechanisms · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou 510120 China

Breast Tumor Center Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou 510120 China

Medical Research Center Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou 510120 China

Department of Immunology School of Basic Medical Sciences Southern Medical University Guangzhou Guangdong 510515 China

Department of Endocrinology Sun Yat‐sen Memorial Hospital, Sun Yat‐sen University Guangzhou 510120 China

The First Clinical Medical College Lanzhou University Lanzhou 730000 China

Department of Cellular and Molecular Diagnostics Center Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou 510120 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Guangdong Provincial Department of Science and Technology

References (55)

Show source-provided references
1. 10.1016/j.pharmthera.2014.10.00110.1016/j.pharmthera.2014.10.001 ↗
2. 10.1186/1471-2407-14-76910.1186/1471-2407-14-769 ↗
3. 10.3892/ol.2016.473010.3892/ol.2016.4730 ↗
4. 10.1074/jbc.M111.30700910.1074/jbc.M111.307009 ↗
5. 10.1038/nrc379210.1038/nrc3792 ↗
6. 10.1038/s41568-021-00340-610.1038/s41568-021-00340-6 ↗
7. 10.1038/s41389-018-0083-110.1038/s41389-018-0083-1 ↗
8. 10.1038/s41392-019-0101-610.1038/s41392-019-0101-6 ↗
9. 10.1038/s41580-020-00315-910.1038/s41580-020-00315-9 ↗
10. 10.1038/s41467-019-08911-w10.1038/s41467-019-08911-w ↗
11. 10.1186/s13045-014-0090-410.1186/s13045-014-0090-4 ↗
12. 10.1186/s13059-017-1348-210.1186/s13059-017-1348-2 ↗
13. 10.1016/j.cell.2017.04.01110.1016/j.cell.2017.04.011 ↗
14. 10.1016/j.molcel.2013.11.00410.1016/j.molcel.2013.11.004 ↗
15. 10.1038/s41416-022-01819-110.1038/s41416-022-01819-1 ↗
16. 10.1038/s41392-023-01725-910.1038/s41392-023-01725-9 ↗
17. 10.1007/s00432-022-04526-910.1007/s00432-022-04526-9 ↗
18. 10.1007/s10585-022-10172-910.1007/s10585-022-10172-9 ↗
19. 10.1007/s10555-024-10178-710.1007/s10555-024-10178-7 ↗
20. Pollan S. G. · Am. J. Clin. Exp. Urol. · 2021 · 9 · 350
21. 10.1038/aps.2017.18910.1038/aps.2017.189 ↗
22. 10.3390/ijms2303172610.3390/ijms23031726 ↗
23. 10.1016/j.pharmthera.2014.10.00110.1016/j.pharmthera.2014.10.001 ↗
24. 10.1186/1471-2105-15-31110.1186/1471-2105-15-311 ↗
25. 10.1074/jbc.M109.09074610.1074/jbc.M109.090746 ↗
26. 10.1042/bj318004110.1042/bj3180041 ↗
27. 10.1242/jcs.0256210.1242/jcs.02562 ↗
28. 10.1074/jbc.273.27.1710210.1074/jbc.273.27.17102 ↗
29. 10.1523/JNEUROSCI.2769-16.201610.1523/JNEUROSCI.2769-16.2016 ↗
30. 10.1074/jbc.M00897220010.1074/jbc.M008972200 ↗
31. 10.1074/jbc.M109.09074610.1074/jbc.M109.090746 ↗
32. 10.1074/jbc.M20294520010.1074/jbc.M202945200 ↗
33. 10.1038/s41421-023-00533-310.1038/s41421-023-00533-3 ↗
34. 10.1002/advs.20220711810.1002/advs.202207118 ↗
35. 10.1016/j.celrep.2016.08.01510.1016/j.celrep.2016.08.015 ↗
36. Yang L. · Elife · 2022 · 11 · 1726
37. 10.3892/etm.2021.1007610.3892/etm.2021.10076 ↗
38. 10.21037/tau-21-82010.21037/tau-21-820 ↗
39. 10.3389/fgene.2021.80762810.3389/fgene.2021.807628 ↗
40. 10.7150/jca.5455610.7150/jca.54556 ↗
41. 10.3389/pore.2023.161087010.3389/pore.2023.1610870 ↗
42. 10.1089/dna.2021.023510.1089/dna.2021.0235 ↗
43. 10.1002/kjm2.1260610.1002/kjm2.12606 ↗
44. 10.1016/j.bcp.2024.11624610.1016/j.bcp.2024.116246 ↗
45. 10.3389/fphar.2024.127420910.3389/fphar.2024.1274209 ↗
46. 10.1016/j.ejmech.2021.11356910.1016/j.ejmech.2021.113569 ↗
47. 10.3390/ijms2312638110.3390/ijms23126381 ↗
48. 10.1021/jacs.8b0800810.1021/jacs.8b08008 ↗
49. Coan M. · Nat. Rev. Genet. · 2024 · 578 · 6381
50. 10.1016/j.jconrel.2011.01.03010.1016/j.jconrel.2011.01.030 ↗
51. 10.1038/s41573-021-00219-z10.1038/s41573-021-00219-z ↗
52. 10.1186/s13045-022-01230-610.1186/s13045-022-01230-6 ↗
53. 10.1093/nar/gkad104210.1093/nar/gkad1042 ↗
54. 10.1186/s13045-020-00849-710.1186/s13045-020-00849-7 ↗
55. 10.1080/15476286.2019.164958410.1080/15476286.2019.1649584 ↗